Cancer Dependencies: PRMT5 and MAT2A in MTAP/p16-Deleted Cancers
| Autor: | Peter Kalev, Katya Marjon, Kevin Marks |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
0301 basic medicine
Cancer Research Protein arginine methyltransferase 5 Cancer Cell Biology Biology medicine.disease law.invention 03 medical and health sciences 030104 developmental biology 0302 clinical medicine Oncology law CDKN2A 030220 oncology & carcinogenesis medicine Cancer research Suppressor |
| Zdroj: | Annual Review of Cancer Biology. 5:371-390 |
| ISSN: | 2472-3428 |
| Popis: | Discovery of targeted therapies that selectively exploit the genetic inactivation of specific tumor suppressors remains a major challenge. This includes the prevalent deletion of the CDKN2A/ MTAP locus, which was first reported nearly 40 years ago. The more recent advent of RNA interference and functional genomic screening technologies led to the identification of hidden collateral lethalities occurring with passenger deletions of MTAP in cancer cells. In particular, small-molecule inhibition of the type II arginine methyltransferase PRMT5 and the S-adenosylmethionine-producing enzyme MAT2A each presents a precision medicine approach for the treatment of patients whose tumors have homozygous loss of MTAP. In this review, we highlight key aspects of MTAP, PRMT5, and MAT2A biology to provide a conceptual framework for developing novel therapeutic strategies in tumors with MTAP deletion and to summarize ongoing efforts to drug PRMT5 and MAT2A. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|